437 related articles for article (PubMed ID: 28050890)
21. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic silence of pleiotrophin by targeted delivery of siRNA and its effect on the inhibition of tumor growth and metastasis.
Zha L; He L; Xie W; Cheng J; Li T; Mohsen MO; Lei F; Storni F; Bachmann M; Chen H; Zhang Y
PLoS One; 2017; 12(5):e0177964. PubMed ID: 28562667
[TBL] [Abstract][Full Text] [Related]
23. Local co-administration of gene-silencing RNA and drugs in cancer therapy: State-of-the art and therapeutic potential.
Larsson M; Huang WT; Liu DM; Losic D
Cancer Treat Rev; 2017 Apr; 55():128-135. PubMed ID: 28363142
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.
Deng Y; Wang CC; Choy KW; Du Q; Chen J; Wang Q; Li L; Chung TK; Tang T
Gene; 2014 Apr; 538(2):217-27. PubMed ID: 24406620
[TBL] [Abstract][Full Text] [Related]
25. Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics.
Zhou Y; Zhang C; Liang W
J Control Release; 2014 Nov; 193():270-81. PubMed ID: 24816071
[TBL] [Abstract][Full Text] [Related]
26. A review of nanocarriers for the delivery of small interfering RNA.
Kesharwani P; Gajbhiye V; Jain NK
Biomaterials; 2012 Oct; 33(29):7138-50. PubMed ID: 22796160
[TBL] [Abstract][Full Text] [Related]
27. Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.
Chen Y; Huang L
Expert Opin Drug Deliv; 2008 Dec; 5(12):1301-11. PubMed ID: 19040393
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive update of siRNA delivery design strategies for targeted and effective gene silencing in gene therapy and other applications.
Abosalha AK; Ahmad W; Boyajian J; Islam P; Ghebretatios M; Schaly S; Thareja R; Arora K; Prakash S
Expert Opin Drug Discov; 2023 Feb; 18(2):149-161. PubMed ID: 36514963
[TBL] [Abstract][Full Text] [Related]
29. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
Akhtar S; Benter I
Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
[TBL] [Abstract][Full Text] [Related]
30. Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review.
Chaturvedi K; Ganguly K; Kulkarni AR; Kulkarni VH; Nadagouda MN; Rudzinski WE; Aminabhavi TM
Expert Opin Drug Deliv; 2011 Nov; 8(11):1455-68. PubMed ID: 21867463
[TBL] [Abstract][Full Text] [Related]
31. Nanostructured Hyaluronic Acid-based Materials for the Delivery of siRNA.
Shah K; Chawla S; Gadeval A; Reddy G; Maheshwari R; Kalia K; Tekade RK
Curr Pharm Des; 2018; 24(23):2678-2691. PubMed ID: 30084325
[TBL] [Abstract][Full Text] [Related]
32. siRNA delivery using nanocarriers - an efficient tool for gene silencing.
Khurana B; Goyal AK; Budhiraja A; Arora D; Vyas SP
Curr Gene Ther; 2010 Apr; 10(2):139-55. PubMed ID: 20353386
[TBL] [Abstract][Full Text] [Related]
33. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Aigner A
J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
[TBL] [Abstract][Full Text] [Related]
34. Efficient intracellular delivery and multiple-target gene silencing triggered by tripodal RNA based nanoparticles: a promising approach in liver-specific RNAi delivery.
Sajeesh S; Lee TY; Kim JK; Son DS; Hong SW; Kim S; Yun WS; Kim S; Chang C; Li C; Lee DK
J Control Release; 2014 Dec; 196():28-36. PubMed ID: 25251899
[TBL] [Abstract][Full Text] [Related]
35. The design and exogenous delivery of siRNA for post-transcriptional gene silencing.
Gilmore IR; Fox SP; Hollins AJ; Sohail M; Akhtar S
J Drug Target; 2004 Jul; 12(6):315-40. PubMed ID: 15545082
[TBL] [Abstract][Full Text] [Related]
36. Nanotechnology-Based Strategies for siRNA Brain Delivery for Disease Therapy.
Zheng M; Tao W; Zou Y; Farokhzad OC; Shi B
Trends Biotechnol; 2018 May; 36(5):562-575. PubMed ID: 29422412
[TBL] [Abstract][Full Text] [Related]
37. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
Gandhi NS; Tekade RK; Chougule MB
J Control Release; 2014 Nov; 194():238-56. PubMed ID: 25204288
[TBL] [Abstract][Full Text] [Related]
38. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.
Golzio M; Mazzolini L; Ledoux A; Paganin A; Izard M; Hellaudais L; Bieth A; Pillaire MJ; Cazaux C; Hoffmann JS; Couderc B; Teissié J
Gene Ther; 2007 May; 14(9):752-9. PubMed ID: 17344906
[TBL] [Abstract][Full Text] [Related]
39. Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.
Zhao J; Feng SS
Nanomedicine (Lond); 2015 Jul; 10(14):2199-228. PubMed ID: 26214357
[TBL] [Abstract][Full Text] [Related]
40. Recent progress in development of siRNA delivery vehicles for cancer therapy.
Kim HJ; Kim A; Miyata K; Kataoka K
Adv Drug Deliv Rev; 2016 Sep; 104():61-77. PubMed ID: 27352638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
